What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis?

Current Opinion in Rheumatology

Volumn 25, Issue 1, 2013, Pages 26-34

  Kain, Renate ^a   Rees, Andrew J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ANCA; ANCA associated vasculitis; autoimmunity; hLAMP 2; pauci immune FNGN

Indexed keywords

AUTOANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2 ANTIBODY; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIBODY TITER; HUMAN; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SMALL VESSEL VASCULITIS;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; EVIDENCE-BASED MEDICINE; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 84871233519     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835b4f8f     Document Type: Review

References (63)

1. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285:606.
2. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophilsand monocytes:toolfordiagnosisand markerof diseaseactivity in Wegener's granulomatosis. Lancet 1985; 1:425-429.
3. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84:1577-1587.
4. Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotiz-ing and crescenticglomerulonephritis. N Engl J Med 1988; 318:1651-1657.
5. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclatureof systemicvasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
6. Jennette JC, Falk RJ, Bacon PA, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 (in press).
7. Jayne DR, Gaskin G, Rasmussen N, et al., European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180-2188.
8. Pagnoux C, Mahr A, Hamidou MA, et al., French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790-2803.
9. De Groot K, Harper L, Jayne DR, et al., EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670-680.
10. Stone JH, Merkel PA, Spiera R, et al., RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
11. Jones RB, Tervaert JW, Hauser T, et al., European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
12. Flossmann O, Berden A, de Groot K, et al., European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488-494.
13. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367:214-223.
14. Kallenberg CG. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: where to go? Clin Exp Immunol 2011; 164 (Suppl 1):1-3.
15. Heeringa P, Little MA. In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations. Arthritis Res Ther 2011; 13:204.
16. Coughlan AM, Freeley SJ, Robson MG. Animal models of antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Immunol 2012; 169: 229-237.
17. Salama AD, Little MA. Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2012; 24:1-7.
18. Kain R, Matsui K, Exner M, et al. A novel class of autoantigensof antineutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181:585-597.
19. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune crescentic glomerulonephritis. Nat Med 2008; 14:1088-1096.
20. Kain R, Tadema H, Mc Kinney EF, et al. High prevalence of autoantibodies to h LAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012; 23:556-566.
21. Etter C, Gaspert A, Regenass S, et al. Antih LAMP2-antibodies and dual positivity for anti-GBM and MPO-ANCA in a patient with relapsing pulmonary-renal syndrome. BMC Nephrol 2011; 12:26.
22. Kawakami T, Ishizu A, Arimura Y, Soma Y. Serum antilysosomal-associated membrane protein-2 antibody levels in cutaneous polyarteritis nodosa. Acta Derm Venereol. 2012. doi: 10.2340/00015555-1418 [Epub ahead of print].
23. Kawakami T, Takeuchi S, Arimura Y, Soma Y. Elevated antilysosomal- associated membrane protein-2 antibody levels in patients with adult Henoch-Schönlein purpura. Br J Dermatol 2012; 166:1206-1212.
24. Roth AJ, Brown MC, Smith RN, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomeru-lonephritis. J Am Soc Nephrol 2012; 23:545-555.
25. Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 2009; 10:623-635.
26. Tanaka Y, Guhde G, Suter A, et al. Accumulation ofautophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000; 406:902-906.
27. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406:906-910.
28. Cheng Z, Fang Q. Danon disease: focusing on heart. J Hum Genet 2012; 57:407-410.
29. Andrejewski N, Punnonen EL, Guhde G, et al. Normal lysosomal morphology and function in LAMP-1-deficient mice. J Biol Chem 1999; 274:12692-12701.
30. Kostich M, Fire A, Fambrough DM. Identification and molecular-genetic characterization of a LAMP/CD68-like protein from Caenorhabditis elegans. J Cell Sci 2000; 113:2595-2606.
31. Wyroba E, Surmacz L, Osinska M, Wiejak J. Phagosome maturation in unicellular eukaryote Paramecium: the presence of RILP, Rab7 and LAMP-2 homologues. Eur J Histochem 2007; 51:163-172.
32. Fukuda M. Lysosomal membrane glycoproteins. J Biol Chem 1991; 266: 21327-21330.
33. Hatem CL, Gough NR, Fambrough DM. Multiple m RNAs encode the avian lysosomal membrane protein LAMP-2, resulting in alternativetransmembrane and cytoplasmicdomains. J Cell Sci 1995; 108:2093-2100.
34. Gough NR, Hatem CL, Fambrough DM. The family of LAMP-2 proteins arises byalternative splicing from asingle gene: characterization of theavian LAMP-2 gene and identification of mammalian homologs of LAMP-2b and LAMP-2c. DNA Cell Biol 1995; 14:863-867.
35. Zhou D, Li P, Lin Y, et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 2005; 22:571-581.
36. Crotzer VL, Glosson N, Zhou D, et al. LAMP-2-deficient human Bcellsexhibit altered MHC class II presentation of exogenous antigens. Immunology 2010; 131:318-330.
37. Demirel O, Jan I, Wolters D, et al. The lysosomal polypeptidetransporter TAPL is stabilized by the interaction with LAMP-1 and LAMP-2. J Cell Sci 2012. [Epub ahead of print]
38. Gough NR, Fambrough DM. Different steady state subcellular distributions of the three splice variants of lysosome-associated membrane protein LAMP-2 are determined largely by the COOH-terminal amino acid residue. J Cell Biol 1997; 137:1161-1169.
39. Wilke S, Krausze J, Büssow K. Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lyso-somal glycocalyx. BMC Biol 2012; 10:62.
40. Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 2008; 68:6623-6633.
41. Kreuzaler PA, Staniszewska AD, Li W, et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol 2011; 13:303-309.
42. Huynh KK, Eskelinen EL, Scott CC, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. Embo J 2007; 26:313-324.
43. Beertsen W, Willenborg M, Everts V, et al. Impaired phagosomal maturation in neutrophils leads to periodontitis in lysosomal-associated membrane protein-2 knockout mice. J Immunol 2008; 180:475-482.
44. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol 2012; 22:407-417.
45. Saftig P, Beertsen W, Eskelinen EL. LAMP-2: a control step for phagosome and autophagosome maturation. Autophagy 2008; 4:510-512.
46. Nimmerjahn F, Milosevic S, Behrends U, et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33:1250-1259.
47. Schmid D, Münz C. Innate and adaptive immunity through autophagy. Immunity 2007; 27:11-21.
48. Schneede A, Schmidt CK, Hölttä-Vuori M, et al. Role for LAMP-2 in endosomal cholesterol transport. J Cell Mol Med 2011; 15:280-295.
49. Saftig P, Eskelinen EL Live longer with LAMP-2. Nat Med 2008; 14:909-910.
50. Huang J, Xu J, Pang S, et al. Age-related decrease of the LAMP-2 gene expression in human leukocytes. Clin Biochem 2012; 45:1229-1232.
51. Furuta K, Yang XL, Chen JS, et al. Differential expression of the lysosome-associated membrane proteins in normal human tissues. Arch Biochem Biophys 1999; 365:75-82.
52. Amos B, Lotan R. Modulation of lysosomal-associated membrane glycopro-teins during retinoic acid-induced embryonal carcinoma cell differentiation. J Biol Chem 1990; 265:191 92-19198.
53. Nabi IR, Dennis JW. The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. Glycobiology 1998; 8:947-953.
54. Carlsson SR, Fukuda M. The polylactosaminoglycans of human lysosomal membrane glycoproteins lamp-1 and lamp-2. Localization on the peptide backbones. J Biol Chem 1990; 265:20488-20495.
55. Lee N, Wang WC, Fukuda M. Granulocytic differentiation of HL-60 cells is associated with increase of poly-N-acetyllactosamine in Asn-linked oligosac-charides attached to human lysosomal membrane glycoproteins. J Biol Chem 1990; 265:20476-20487.
56. Pryor PR. Analyzing lysosomes in Live Cells. Methods Enzymol 2012; 505:145-157.
57. Colley KJ. Golgi localization of glycosyltransferases: more questions than answers. Glycobiology 1997; 7:1-13.
58. Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009; 19:936-949.
59. Zuliani L, Graus F, Giometto B, et al. Central nervoussystem neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83:638-645.
60. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87:671-678.
61. Fervenza FC, Specks U. Vasculitis: will LAMP enlighten us about ANCA-associated vasculitis? Nat Rev Nephrol 2012; 8:318-320.
62. Flint SM, Savage CO. Anti-LAMP-2 autoantibodies in ANCA-associated pauci-immune glomerulonephritis. J Am Soc Nephrol 2012; 23:378-379.
63. Kerjaschki D, Ullrich R, Exner M, et al. Induction ofpassive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor-associated protein. J Exp Med 1996; 183:2007-2013.